EMEA-001207-PIP01-11-M01 - paediatric investigation plan
Obinutuzumab
PIPHuman
Roche Registration GmbH
E-mail: global.paediatrics@roche.com
Tel. +41 616879411
P/0196/2021 : EMA decision of 10 May 2021 on the acceptance of a modification of an agreed paediatric investigation plan for obinutuzumab (Gazyvaro), (EMEA-001207-PIP01-11-M01)